India Pharma Outlook Team | Monday, 22 December 2025
The Indian Pharmaceutical Alliance (IPA) has revealed $15 million expenditure to build a dedicated pharmaceutical quality institute in Ahmedabad. Along with drug regulatory bodies, the project will entail cooperation with state and federal government officials, hence strengthening India's resolve toward world pharmaceutical excellence.
Speaking at IPC 2025 during a panel discussion on Viksit Bharat 2025, Sudarshan Jain, General Secretary of the Indian Pharmaceutical Alliance, said that quality is the most important thing for research, production, and marketing in the pharmaceutical industry.
"This institute will enable voluntary adherence to tougher quality standards, therefore supporting businesses in rebuilding and strengthening trust, which is especially important for the worldwide reputation of Brand India," he said.
Rising demand for medications, biosimilars, and active pharmaceutical ingredients (APIs) as well as increased regulatory attention coincide with the action. Furthermore, emphasizing the need of education and training for industry workers is the application of sophisticated technologies such artificial intelligence in pharmaceutical processes.
Also Read: Merck Signs Agreement to Lower Medicine Costs in the US
Including worldwide summits, R&D help programmes, and digital health projects, IPA has long backed projects meant to promote excellence and creativity. To foster industry-wide excellence and boost India's standing as a major pharmaceutical centre, the organisation also holds Global Pharmaceutical Quality Summits.
Establishing this quality institute helps the IPA to build a methodical forum for knowledge-sharing, skill development, and adherence to best-in-class production standards so that India keeps its reputation as a dependable source of premium medicines for world markets.
